Evolution of the Average Target: Filana Therapeutics, Inc.

Evolution of the Average Target - Filana Therapeutics, Inc.

Evolution of the Target Price: Filana Therapeutics, Inc.

Evolution of the Target Price - Filana Therapeutics, Inc.

Changes in Analyst Recommendations: Filana Therapeutics, Inc.

6.QLT84INojYaGpI86zCP1I-vzlD1jCK6UkVasXs52f3o.OOGvhuIdyuPEncEXjXOGaqmq53IAccLdxmXVa4caSh4ih463uyD81Nnl2g~e0f507c905c0f707a9014c1ba970aab4
26/11/24 HC Wainwright Downgrades Cassava Sciences to Neutral From Buy MT
08/10/24 HC Wainwright Upgrades Cassava Sciences to Buy From Neutral, $116 Price Target MT
01/07/24 JonesTrading Downgrades Cassava Sciences to Hold From Buy MT
01/07/24 HC Wainwright Downgrades Cassava Sciences to Neutral From Buy MT
17/05/24 HC Wainwright Adjusts Price Target on Cassava Sciences to $131 From $124, Maintains Buy Rating MT
25/01/23 B. Riley Cuts Cassava Sciences' PT to $28 From $44 on 'Uninterpretable' Open-Label Results of Simuflam in Alzheimer's Disease Patients; Keeps Neutral Rating MT
16/11/22 B. Riley Downgrades Cassava Sciences to Neutral From Buy, Notes Challenging Near-Term Catalyst Profile, Prolonged Litigation Mess; Maintains $44 PT MT
11/08/22 B. Riley Securities Lowers Cassava Sciences' Price Target to $44 from $58, Retains Buy Rating MT
06/05/22 B. Riley Lowers Cassava Sciences' Price Target to $58 from $72 to Factor in Increased Pace of Research & Development Expenses; Keeps Buy Rating MT
04/04/22 Univest Securities Starts Cassava Sciences at Sell With $8 Price Target, Says Phase 3 Trials Unlikely to Lead to Commercialization, Expects Further Stock Dilution MT
02/02/22 Maxim Group Adjusts Cassava Sciences Price Target to $110 From $190, Maintains Buy Rating MT
24/01/22 B. Riley Lowers Cassava Sciences' Price Target to $72 from $108 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
07/09/21 Cassava Sciences : B. Riley Lowers Cassava Sciences' PT to $108 from $145 on Investor Concerns Over Alleged Scientific Misconduct; Keeps Buy Rating MT
03/08/21 Cassava Sciences : B. Riley Raises Cassava Sciences' PT to $145 from $111 After Management Q&A on Simufilam, Keeps Buy Rating MT
20/07/21 Cassava Sciences : HC Wainwright Adjusts Cassava Sciences' Price Target to $124 From $97, Keeps Buy Rating MT
15/07/21 Cassava Sciences : Cantor Fitzgerald Downgrades Cassava Sciences to Neutral From Overweight, Adjusts PT to $100 From $73 MT
23/06/21 Cassava Sciences : B. Riley Raises Cassava Sciences' PT to $111 from $78 on Regulatory Tailwinds for Late-Stage AD Therapeutic, Keeps Buy Rating MT
27/04/21 Cassava Sciences : B. Riley Starts Cassava Sciences at Buy With $78 Price Target MT
17/03/21 Cassava Sciences : JonesTrading Initiates Cassava Sciences at Buy with $110 Price Target MT
23/02/21 Cassava Sciences : HC Wainwright & Co. Adjusts Price Target on Cassava Sciences, Inc to $97 From $66, Maintains Buy Rating MT
16/02/21 Cassava Sciences : Maxim Raises Cassava Sciences' Price Target to Street-High $80 from $14, Keeps Buy Rating MT
16/02/21 Cassava Sciences : HC Wainwright Adjusts Cassava Sciences' Price Target to $66 From $20, Keeps Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +1,429.05%
+38.3%
+15.44%
+7.53%
+12.65%
+17.64%
+59.48%
+30.16%
+17.66%
+60.27%
Average +168.82%
Weighted average by Cap. +26.55%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.4251USD
Average target price
6.500USD
Spread / Average Target
+1,429.05%
High Price Target
8.000USD
Spread / Highest target
+1,781.91%
Low Price Target
5.000USD
Spread / Lowest Target
+1,076.19%

Analyst Consensus Detail

Analyst consensus - Filana Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Filana Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Filana Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FLNA Stock
  4. Consensus Filana Therapeutics, Inc.